beta-solamarine, solamargine
| Name | Solamargine | ||
| PubChem CID | 73611 | ||
| Molecular Weight | 868.1g/mol | ||
| Synonyms |
beta-solamarine, solamargine |
||
| Formula | C₄₅H₇₃NO₁₅ | ||
| SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)NC1 | ||
| InChI | 1S/C45H73NO15/c1-19-9-14-45(46-17-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(53)34(51)32(49)22(4)56-41)37(54)38(29(18-47)58-42)59-40-35(52)33(50)31(48)21(3)55-40/h7,19-22,24-42,46-54H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1 | ||
| InChIKey | MBWUSSKCCUMJHO-ZGXDEBHDSA-N | ||
| CAS Number | 20311-51-7 | ||
| ChEMBL ID | CHEMBL443114 | ||
| ChEBI ID | CHEBI:9185 | ||
| Herb ID | HBIN044265 | ||
| Drug Bank ID | DB12700 | ||
| KEGG ID | C10819 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | BaiMaoTeng | ||
| Use Part | Whole Herb | ||
| Habitat | China | ||
| Flavor | Sweet, Bitter | ||
| Meridian Tropism | Liver, Gallbladder, Kidney | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Solanales
-->Family: Solanaceae
-->Genus: Solanum
-->Species: Solanum lyratum
|
||
| Chineses Pinyin | LaJiao | ||
| Use Part | Fruit | ||
| Habitat | China | ||
| Flavor | Pungent | ||
| Meridian Tropism | Heart, Spleen | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Solanales
-->Family: Solanaceae
-->Genus: Capsicum
-->Species: Capsicum annuum
|
||
| Chineses Pinyin | LongKui | ||
| Use Part | Aerial Parts | ||
| Habitat | China | ||
| Flavor | Bitter | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Solanales
-->Family: Solanaceae
-->Genus: Solanum
-->Species: Solanum nigrum
|
||
| Chineses Pinyin | QianNianBuLanXin | ||
| Use Part | Whole Herb | ||
| Habitat | Shaanxi, GanSu, ShanDong, HeNan, HuNan, JiangXi, ZheJiang, FuJian, GuangDong, GuiZhou, YunNan, HaiNan, XiZang, TaiWan | ||
| Flavor | Sweet, Bitter | ||
| Chineses Pinyin | TianQieZi | ||
| Use Part | Fruit, Seed, Leaf | ||
| Habitat | YunNan, HeNan, HuBei, HuNan | ||
| Flavor | Bitter | ||
| Pair Name | Solamargine, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Down-regulation | Expression | CCND1 | hsa595 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | SHH | hsa6469 | |
| In Vitro Model | NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| Result | Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids | |||
| Pair Name | Solamargine, Bortezomib | |||
| Partner Name | Bortezomib | |||
| Disease Info | [ICD-11: 2A83] | Multiple myeloma | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | BECN1 | hsa8678 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | MAP1LC3A | hsa84557 | |
| Up-regulation | Expression | MAP1LC3B | hsa81631 | |
| In Vitro Model | ARP-1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_D523 |
| NCI-H929 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_1600 | |
| Result | These findings indicate that SM exerts an anti-MM effect, at least in part, by activating cell autophagy and reveal that SM alone or in combination with BTZ is a potential therapeutic strategy for treating MM. | |||
| Pair Name | Solamargine, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Gene Regulation | Down-regulation | Expression | HOTTIP | KEGG ID N.A. |
| Up-regulation | Expression | microRNA 4726 | hsa100616153 | |
| Down-regulation | Expression | MUC1 | hsa4582 | |
| Down-regulation | Expression | TUG1 | hsa55000 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
| Result | Our study revealed that SM inhibited the growth of HCC and enhanced the anticancer effect of SF through HOTTIP-TUG1/miR-4726-5p/MUC1 signaling pathway. These findings will provide potential therapeutic targets and strategies for the treatment of HCC. | |||
| Pair Name | Solamargine, Gefitinib | |||
| Partner Name | Gefitinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | IGFBP1 | hsa3484 |
| Up-regulation | Expression | SP1 | hsa6667 | |
| Result | We confirmed that SM significantly enhanced the anticancer effect of EGFR-TKIs by regulating the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. This study unravels a novel mechanism and suggests a new potential NSCLC-associated therapy. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. Front Pharmacol. 2022 Aug 10;13:802168. doi: 10.3389/fphar.2022.802168. | Click |
| 2 | Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma. Clin Exp Pharmacol Physiol. 2022 Jun;49(6):674-685. doi: 10.1111/1440-1681.13643. | Click |
| 3 | Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway. Mol Carcinog. 2022 Apr;61(4):417-432. doi: 10.1002/mc.23389. | Click |
| 4 | Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer. Carcinogenesis. 2023 Aug 18;44(6):497-510. doi: 10.1093/carcin/bgad028. | Click |
